Pharmaceutical

Health Canada approves Acadia’s DAYBUE for Rett syndrome

Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.

Oct 18, 2024 - 04:00
Health Canada approves Acadia’s DAYBUE for Rett syndrome
Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.
Read the original article

Tags:

Previous Article

Glaukos eyes FDA approval for ocular therapy after Phase III win

Next Article

Lexicon partners Viatris for global expansion of sotagliflozin

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Clinical notes automation startup Abridge raises $150 million, takes aim at Microsoft Nuance

STAT+: Clinical notes automation startup Abridge raises...

Feb 23, 2024

Routine screening for kidney disease would be cost-effective, study argues

Routine screening for kidney disease would be cost-effe...

May 23, 2023

Sanofi gets grant for optical decoding system for deter...

Apr 25, 2024